The role for NES1 serine protease as a novel tumor suppressor

Cancer Research

Volumn 58, Issue 21, 1998, Pages 4782-4786

  Goyal, Jaya ^a   Smith, Karen M ^b   Cowan, Janet M ^a   Wazer, David E ^a   Lee, Sam W ^c   Band, Vimla ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SERINE PROTEINASE;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER INHIBITION; CHROMOSOME 19Q; CONTROLLED STUDY; EPITHELIUM CELL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 19; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; KALLIKREINS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANSFECTION;

EID: 0032212444     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Farber, E. The multistep nature of cancer development. Cancer Res., 44: 4217-4223, 1984.
2. Liu, X-L., Wazer, D. E., Watanabe, K., and Band, V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res., 56: 3371-3379, 1996.
3. Biochemistry. L. Stryer (ed.), 3rd ed., pp 226-259. New York: W. H. Freeman and Company, 1988.
4. Wang, M-H., Gonias, S. L., Skeel, A., Wolf, B. B., Yoshimura, T., and Leonard, E. J. Proteolytic activation of single-chain precursor macrophage-stimulating protein by nerve growth factor-γ and epidermal growth factor-binding protein, members of the kallikrein family. J. Biol. Chem., 269: 13806-13810, 1994.
5. Degen, S. J. F., Rajput, B., and Reich, E. The human tissue plasminogen activator gene. J. Biol. Chem., 261: 6972-6980, 1986.
6. Naka, D., Ishii, T., Yoshiyama, Y., Miyazawa, K., Hara, H., Hishida, T., and Kitamura, N. Activation of hepatocyte growth factor by proteolytic conversion of a single chain form to a heterodimer. J. Biol. Chem., 267: 20114-20119, 1992.
7. Watt, K. W., Lee, P. J., M'Timkulu, T., Chan, W. P., and Loor, R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl. Acad. Sci. USA, 83: 3166-3170, 1986.
8. Becker, C., and Lilja, H. Individual prostate-specific antigen (PSA) forms as prostate tumor markers. Clin. Chim. Acta, 257: 117-132, 1997.
9. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P. I., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
10. Lamszus, K., Jin, L., Fuchs, A., Shi, E., Chowdhury, S., Yao, Y., Polverini, P. J., Laterra, J., Goldberg, I. D., and Rosen, E. M. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice. Lab. Invest., 76: 339-353, 1997.
11. Beviglia, L., Matsumoto, K., Lin, C. S., Ziober, B. L., and Kramer, R. H. Expression of the c-met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int. J. Cancer, 74: 301-309, 1997.
12. Bright, R. K., Vocke, C. D., Emmert-Buck, M. R., Duray, P. H., Solomon, D., Fetsch, P., Rhim, J. S., Linehan, W. M., and Topalian, S. L. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res., 57: 995-1002, 1997.
13. Webber, M. M., Bello, D., Kleinman, H. K., Wartinger, D. D., Williams, D. E., and Rhim, J. S. Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis (Lond.), 17: 1641-1646, 1996.
14. Narayan, P., and Dahiya, R. Establishment and characterization of a human primary prostate adenocarcinoma cell line (ND-1). J. Urol., 148: 1600-1604, 1992.
15. Zugmaier, G., Paik, S., Wilding, G., Knabbe, C., Bano, M., Lupu, R., Deschauer, B., Simpson, S., Dickson, R. B., and Lippman, M. Transforming growth factor β1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. Cancer Res., 51: 3590-3594, 1991.
16. Band, V., Zajchowski, D., Kulesa, V., and Sager, R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc. Natl. Acad. Sci. USA, 87: 463-467, 1990.
17. Heim, S., and Mitelman, F. (eds.). Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells. New York: John Wily and Sons, Inc., 1995.
18. Anisowicz, A., Sotiropoulou, G., Stenman, G., Mok, S. C., and Sager, R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol. Med., 2: 624-636, 1996.
19. Yu, H., Diamandis, E. P., and Sutherland, D. J. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin. Biochem. 27: 75-79, 1994.
20. Cohen, P., Graves, H. C. B., Peehl, D. M., Kamarei, M., Giudice, L. C., and Rosenfeld, R. G. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 75: 1046-1053, 1992.
21. Rajah, R., Katz, L., Nunn, S., Solberg, P., Beers, T., Cohen, P. Insulin-like growth factor binding protein (IGFBP) proteases: functional regulators of cell growth. Prog. Growth Factor Res., 6: 273-284, 1995.
22. Ho, P. J., and Baxter, R. C. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostate hyperplasia. Clin. Endocrinol., 46: 145-154, 1997.
23. Clemmons, D. R., Camacho-Hubner, C., Coronada, E., and Osborne, C. K. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines; correlation with estrogen status. Endocrinology, 127: 2679-2686, 1990.
24. Gill, Z. P., Perks, C. M., Newcomb, P. V., and Holly, J. M. P. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J. Biol. Chem., 272: 25602-25607, 1997.